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Introduction
It remains a challenge to discuss every 3 months the published
literature on the pathology of lymphomas. A pleasant chal-
lenge, because I need to read many interesting works, but also
an impossible one: I cannot read everything. Nevertheless, I
hope that also this month, I can provide the readership with an
interesting summary of my personal selection.
Biology of lymphoma
Hodgkin lymphoma
CD30 expression is a hallmark of Hodgkin lymphoma (HL),
and this is associated with activation of the nuclear factor-κB
(NF-κB) pathway. Epstein-Barr virus (EBV) latent membrane
protein-1 (LMP-1) and ligand-independent signaling by
overexpressed CD30 are both known to cause activation of
NF-κB in lymphomas, but in normal cells hyperactivation of
NF-κB triggers cellular senescence and apoptosis. Ishikawa et
al. [1] show that IκB-ζ, an inducible regulator of NF-κB, is
constitutively expressed in Burkitt lymphoma (BL) and HL
cell lines. In addition, immunohistochemically nuclear IκB-ζ
was positive in BL cells and Hodgkin and Reed-Sternberg
(HRS) cells. Expression of LMP-1 and CD30 increased
IκB-ζ expression at the transcriptional level. IκB-ζ promoter
was regulated by activation of the NF-κB-inducing kinase
(NIK)/IκB kinase/NF-κB pathway via the carboxyl-terminal
tumor necrosis factor (TNF) receptor-associated factor
(TRAF)-interacting regions of LMP-1 and CD30.
Interestingly, IκB-ζ inhibited NF-κB activation by LMP-1
and CD30. The results suggest that NF-κB-induced IκB-ζ
negatively modulates NF-κB hyperactivation, resulting in a
fine balance that ultimately endows a net evolutionary benefit
to the survival of BL and HL cells. This work shows how
complicated checks and balances are in normal and neoplastic
cells and how difficult it is to deduct function from mere
immunohistochemical analysis of tumors.
Another example is provided by Oelmann et al. [2] who
studied expression of IL-1beta, IL-1R1, and IL-1R2 in 17
HL by mRNA in situ hybridization (ISH). Signaling through
the IL-1-receptor type 1 (IL-1R1), IL-1 is required for initiation
andmaintenance of diverse activities of the immune system, and
a second receptor, IL-1R2, blocks IL-1 signal transduction.
IL-1beta expressing cells, morphologically consistent with
endothelial cells and fibroblasts, occurred in all HL tissues with
elevated transcript levels in areas of active fibrosis. HRS cells of
all cases expressed low IL-1R1 transcript levels in some tumor
cells and high levels of IL-1R2 in large proportions of HRS
cells. Only few bystander cells showed low levels of IL-1R1
and IL-1R2 RNA. HL patient sera carried variably amounts of
IL-1R2 protein with significantly increased titers in patients with
active disease compared to patients in complete remission and
cont ro l ind iv idua l s wi thou t HL. Wes te rn blo t s
and co-immunoprecipitations showed binding of the IL-1R2 to
the intracellular IL-1R-accessory protein (IL-1IRAcP). These
data suggest functions of the IL-1R2 as a Bdecoy-receptor^
sequestrating paracrine IL-1 extracellularly and intracellularly
by engaging IL-1IRAcP, thus depriving IL1-R1 molecules of
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their extracellular and intracellular ligands. Expression of IL1-
R2 by HRS cells seems to contribute to local and systemic
modulation of immune function in HL.
B cell lymphomas
Nowadays, whole genome or exome sequencing (WGS;
WES) has become a widely available tool so we can expect
rapid increase in the knowledge on genetic changes in many
tumors. Peveling-Oberhag et al. [3] investigated splenic mar-
ginal zone lymphoma (sMZL) using this technique in two
cases. They found 25 different somatic mutations, including
known mutations in the NOTCH2 and MYD88 genes, but the
other 23 had not been associated with SMZL before.
However, in none of 24 additional sMZL, these latter muta-
tions were also found. Therefore, this approach was not very
successful in finding recurrent genetic alterations in this study,
but further work is needed.
The gene encoding the lysine-specific histone methyltrans-
ferase KMT2D has emerged as one of the most frequently
mutated genes in follicular lymphoma (FL) and diffuse large
B cell lymphoma (DLBCL), but the biological consequences
of these mutations are not known. Two groups of researchers
took on the challenge to determine the role of these mutations
in lymphoma development and come with similar results.
Ortega-Molina et al. [4] show in mouse models that
KMT2D affects methylation of histone H3 and expression of
a set of genes, including those in the CD40, JAK-STAT, Toll-
like receptor, and B cell receptor signaling pathways. Other
KMT2D target genes include frequently mutated tumor sup-
pressor genes such as TNFAIP3, SOCS3, and TNFRSF14.
Furthermore, they show that KMT2D functions as a tumor
suppressor and that its loss in B cells results in diminished B
cell differentiation and class switch recombination as well as
lymphoma development. Zhang et al. [5] show that FL- and
DLBCL-associated KMT2D mutations impair KMT2D enzy-
matic activity, leading to diminished global H3K4 methylation
in germinal-center (GC) B cells and DLBCL cells. Conditional
deletion of KMT2D early during B cell development, but not
after initiation of the GC reaction, results in an increase in GC
B cells and enhances B cell proliferation in mice. Moreover,
genetic ablation of KMT2D in mice overexpressing Bcl2 in-
creases the incidence of GC-derived lymphomas resembling
human tumors. These findings suggest that KMT2D acts as a
tumor suppressor gene whose early loss facilitates lymphoma-
genesis by remodeling the epigenetic landscape of the cancer
precursor cells.
BL and FL both have features of GC B cells but are bio-
logically and clinically quite distinct. Kretzmer et al. [6] per-
formed whole-genome bisulfite, genome and transcriptome
sequencing in 13 immunoglobulin (IG)-MYC translocation-
positive BL, 9 BCL2 translocation-positive FL and 4 normal
GC B cell samples. There was different methylation of
intragenic regions between BL and FL that strongly correlated
with expression of associated genes. The results demonstrate a
tight connection between somatic mutation, DNA methyla-
tion, and transcriptional control in key B cell pathways
deregulated differentially in different types of GC B cell
lymphomas.
Hartmann et al. [7] tried to gain better understanding of the
signaling molecules in the microenvironment of B cell sam-
ples, which in the end, might lead to new treatment ap-
proaches. They analyzed B-CLL infiltrated lymph nodes from
43 different patients for expression of the chemokine CCL3,
Ki-67, macrophages, and Tcell subsets by immunohistochem-
istry. CCL3 expression was detected in 24 of 43 cases (56 %),
particularly within the proliferation centers, which was asso-
ciated with higher numbers of CD3+ T cells and CD57+ cells,
and higher proliferation rates. Obviously, more data are re-
quired before this type of insight results in specific treatments.
Activated B cell (ABC) DLBCL relies on B cell receptor
(BCR) signaling but only a part of patients benefit form BCR
pathway inhibition. Young et al. [8] developed a series of
ABC cells that differed solely with respect to the immuno-
globulin heavy chain variable region (IgH v). The viability
of one VH4-34 ABC line and the ability of its BCR to bind
to its own cell surface depended autoreactivity to self-glyco-
proteins. The BCR of another ABC line reacted with self-
antigens in apoptotic debris, and the survival of a third ABC
line was sustained by reactivity of its BCR to an idiotypic
epitope in its own V region. The authors conclude that a di-
verse set of self-antigens is responsible for maintaining the
survival of ABC DLBCL cells. As a therapy, removal of such
stimuli seems not feasible, but addressing the BCR is a poten-
tial alternative.
T cell lymphoma
Some lymphomas are closely related to specific environments
in the body. An example is the tight relation with infiltration in
the epithelium of some cutaneous Tcell lymphomas (T-NHL).
Adachi et al. [9] investigated normal hair follicles, which are
known to contribute to skin dendritic cell homeostasis through
chemokine production. They demonstrate that CD4(+) and
CD8(+) skin-resident memory T cells (TRM cells), which
are responsible for long-term skin immunity, reside predomi-
nantly within the hair follicle epithelium of the normal skin.
Hair follicle expression of IL-15 was required for CD8(+)
TRM cells, and IL-7 for CD8(+) and CD4(+) TRM cells, to
exert influx in the hair follicle epithelium. Also in a model of
cutaneous T-NHL, epidermotropic CD4(+) TRM lymphoma
cell localization depended on the presence of hair follicle-
derived IL-7. These findings implicate hair follicle-derived
cytokines as regulators of malignant and non-malignant
TRM cell tissue residence, and they suggest that the cytokines
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may be targeted therapeutically in inflammatory skin diseases
and lymphoma.
Asmentioned above for sMZL,WGSwas performed by da
Silva Almeida et al. [10] on normal and tumor samples of 25
Sézary syndrome (SS) and 17 other cutaneous (c) T-NHL
patients. They present a distinctive pattern of somatic copy
number alterations in SS, including highly prevalent chromo-
somal deletions involving the TP53, RB1, PTEN, DNMT3A,
and CDKN1B tumor suppressors. Mutation analysis identi-
fied a broad spectrum of somatic mutations in key genes in-
volved in epigenetic regulation (TET2, CREBBP, KMT2D
(MLL2), KMT2C (MLL3), BRD9, SMARCA4, and CHD3)
and signaling, including MAPK1, BRAF, CARD11, and
PRKG1 mutations driving increased MAPK, NF-κB, and
NFAT activity upon T cell receptor stimulation. The authors
conclude that their findings provide new insights into the ge-
netics of SS and cT-NHL and support the development of
personalized therapies targeting key oncogenically activated
signaling pathways for the treatment of these diseases.
However, for me, this study, like many other similar studies,
provide a large number of genetic changes in certain tumors,
but provide actually quite little insight and reveal no unknown
target for new drugs.
Ohtani et al. [11] give further insight in the pathogenesis of
angioimmunoblastic T-NHL (AITL). In AITL, there is expres-
sion of CXCL13 which is used as a tumor marker. However, it
is not clear whether the CXCL13(+) cells are the neoplastic
TFH cells or follicular dendritic cells (FDCs). Using double-
labeling immunofluorescent microscopy, they first showed
that CXCL13 was mainly expressed in FDCs of normal ger-
minal centers. In 28 of 33 AITL cases, CXCL13 was also
mainly expressed in FDCs as a meshwork pattern but in the
other five cases, CXCL13 was expressed in neoplastic cells.
Triple-labeling immunofluorescent microscopy showed that
the CXCL13(+) FDC meshwork in AITL harbored both neo-
plastic cells and B cells. CXCR5, the receptor of CXCL13,
was expressed in neoplastic cells in AITL. These data indicate
that neoplastic cells in some cases of AITL preserve a certain
level of TFH-cell function since neoplastic cells and B cells
are closely enmeshed in the CXCL13(+) cell-rich FDC mesh-
work in a similar way as in normal germinal centers.
Nasal natural killer T cell lymphoma (NKTL) is a highly
malignant tumor that is closely associated with Epstein-Barr
virus (EBV) infection. Latent membrane protein 1 (LMP1) is
encoded by EBVand plays an important role in EBV-induced
cell transformation. Therefore, Sun et al. [12] assessed the
function of LMP1 as a stimulant of NKTL progression and
the underlying mechanism. A human EBV-positive NKTL
cell line (SNK-6) was transfected with pcDNA3.1-LMP1,
LV-LMP1 shRNA, or LV-eukaryotic translation initiation fac-
tor 4E (eIF4E)-shRNA. Their results showed that LMP1 was
highly expressed in SNK-6 cells compared with control
groups. Following pretreatment with LMP1 shRNA, the
proliferation of SNK-6 cells was inhibited and resulted in a
G0/G1 phase arrest. A reduction in invasion and migration
was also observed. LMP1 silencing promoted cell apopto-
sis. Further mechanistic analysis suggested that LMP1
overexpression induced the expression of eIF4E, while
eIF4E-shRNA dramatically attenuated the increase in cell
proliferation, invasion, migration, and the inhibition of ap-
optosis triggered by LMP-1 upregulation. Moreover, the
effect of LMP1 on eIF4E expression was mediated by the
NF-κB pathway.
Epidemiology of lymphoma
The genetic susceptibility for the development of disease can
only be unraveled when the disease is well defined. Delahaye-
Sourdeix et al. [13] provide a fine example, by showing that a
polymorphism close to aHLA gene is associated with Epstein-
Barr virus (EBV)-positive HL (both mixed and nodular scle-
rosis type) but not with EBV negative HL. They could do this
since they had a large series of cases (1200), which was com-
pared with 5726 controls. The results were confirmed in an
independent series of 468 cases and 551 controls.
De Montpréville et al. [14] describe their experience with
16 cases of lymphoproliferative disorders (PTLD) after lung
transplantation. Their patients (15–63 years of age) were
mostly (12/16) EBV seropositive at the time of transplanta-
tion. Eleven cases, occurring within 18months after transplan-
tation, had EBV+ DLBCL. Lungs and/or thoracic lymph
nodes were often involved (n=8). Two patients are in com-
plete remission at 26 and 216 months. Nine patients died 8.0
±6.5 months after diagnosis. Of the five cases with late PTLD
occurring 4–23 years after transplantation, one had pulmonary
lymphomatoid granulomatosis (the only endothoracic case),
one cutaneous large Tcell lymphoma, two had anaplastic large
cell lymphomas, and one HL. Two of the five cases were
EBV-negative, including one followed by a second EBV+
positive PTLD after 8 years of complete remission. Two pa-
tients were alive and well (follow-up: 44 and 151 months).
These data are in line with the suggestion that early PTLD is
generally an immune deficiency and EBV-associated disease,
but that late lesions have a different and variable pathogenesis.
Defining entities
Hodgkin lymphoma
The distinction between extensive progressive transformed
germinal centers (PTGC) and nodular lymphocyte predomi-
nant (NLP) HL is not easy. The presence of regular large
CD20-positive cells has been described as indicative of
NLPHL, but in practice, I prefer the criterium that the lesions
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need to have a mass effect, a disturbance of the lymph node
architecture. Hartmann et al. [15] describe the morphologic
features of 160 cases of PTGC for better delineation of
PTGC from early involvement by NLPHL (although I do
not know what early involvement really means… it is in my
mind NLPHL or not). They had 93 patients with PTGC who
never developed a lymphoma, 23 patients with synchronous
PTGC and NLPHL, and 44 patients with PTGC with anteced-
ent or subsequent history of lymphoma. The authors describe
five patterns of PTGC that reflected progressive dismantling
of germinal centers and here was no difference in the distri-
bution of patterns 1 to 4 among the three groups of PTGC;
however, in patients showing synchronous involvement of
PTGC and NLPHL, pattern 5, which resembles a naïve B cell
follicle, was significantly more frequent. The problem with
this study and similar ones is a common problem in patholo-
gy: we do not have a gold standard, so we tend to formulate
criteria based on circular argumentation.
A typical feature of NLPHL is the increased number of
CD57-positive CD4+ Tcells [16], cells that are normally pres-
ent in the germinal center of lymphoid follicles. They show
that the cells directly rosetting LP cells are positive for CD57
and/or for two markers of T-follicular helper (TFH) cells, PD-
1, and BCL-6. Furthermore, by flow cytometry, more than
90% of CD57+ Tcells express Bcl6 and PD-1, whereas about
half of the PD-1+ Tcells are CD57+, both in normal tonsil and
in NLPHL.
Eladl et al. [17] describe the clinicopathologic features of 25
cases of NLPHL and point to another feature: the presence of
macrophages. The median age at onset of their patients was
56 years (range: 6–82 years) with male predominance (64 %).
All patients presented with lymph node enlargement with pre-
dilection for cervical LNs. Seven cases (28 %) had a medias-
tinal lesion, and four (16%) had extranodal involvement. Most
cases (76 %) presented with early clinical stages. After median
follow-up of 44 months, both of overall and progression-free
survival rates were 95%. The presence of >5%CD68+ cells in
NLPHL was significantly associated with older age at diagno-
sis and lower CR rate after initial treatment (42.9 vs 91.7 %).
The presence of >5 % CD163+ cells was significantly corre-
lated with presence of B symptoms (40 vs 0 %). However,
there was no impact on overall survival of the presence of
CD68- or CD163-positive macrophages.
Classical (c) HL is defined by morphology and aberrant B
cell program. Rare cases of otherwise typical HL have strong
CD20 expression. Benharrough et al. [18] describe 24 (13 %
of their 166 cHL cases, which seems to me quite high) such
cases. Except for an older age and a lower expression of
CD15, no differences with CD20-negative HL were found,
indicating that CD20 expression may be accepted in the
diagnosis of cHL. I am not sure whether high CD20 and
low CD15 is really acceptable for a HL diagnosis for me;
these remain cases with important differential diagnosis of
EBV-related disease or so-called gray zone cases in a ma-
jority of HRS cells in cHL.
B cell lymphomas
Nodal marginal zone lymphoma (NMZL) remains an ill-
recognized entity that easily may be misdiagnosed as FL. In
this issue of the Journal of Hematopathology, van den Brand
et al. [19] hypothesize that many translocation t(14;18)-nega-
tive FL may actually be NMZL. In another study of the same
author, he investigates whether this mistake is clinically rele-
vant [20]. The clinical features of 56 patients with NMZL
were compared to 46 patients with FL. Both patient groups
had a largely similar clinical presentation, but patients with FL
had a higher stage at presentation, more frequent abdominal
lymphadenopathy and bone marrow involvement, and
showed more common transformation into diffuse large B cell
lymphoma (DLBCL) during the course of their disease.
Overall survival and event-free survival were similar for pa-
tients with NMZL and FL, but factors associated with worse
prognosis differed between the two groups. Transformation
into DLBCL was associated with a significantly poorer out-
come in both the groups, but the phenotypes were different:
DLBCL arising in FL was mainly of GBC phenotype, where-
as DLBCL arising in NMZL was mainly of ABC phenotype,
well fitting with the findings mentioned earlier in this review.
Conconi et al. [21] also analyzed transformation in 340 MZL
patients diagnosed and treated between 1995 and 2012: 157
ENMZL, 85 SMZL, and 37 nodal NMZL. With a median
follow-up of 4.8 years, the median overall survival and
progression-free survival of the whole population were 14.5
and 5 years, respectively. Transformation was observed in 13
cases (3.8 %; 5 % of SMZL, 4 % of ENMZL, 3 % of NMZL)
indicating that the risk of transformation across all MZL types
is lower than in FL, which is in contrast with the mentioned
study into NMZL [20].
Choung et al. [22] investigated the presence of t(11;18)
API2-MALT1, t(14;18) IgH-MALT1 translocations and
chromosomes 3 and 18 aneuploidies in 30 ocular MZL,
using fluorescence in situ hybridization (FISH); the
t(14;18) IgH-MALT1 translocation was demonstrated in
only one case, and the t(11;18) API2-MALT1 translocation
was not found; trisomy 3 was observed in three cases, and
five cases showed trisomy 18. The translocation-positive
case also showed trisomy 18. There were no statistically
significant correlations between chromosomal aberrations
and clinical characteristics and treatment responses.
Lymphoplasmacytic lymphoma (LL) secreting IgA or IgG
is rare. Cao et al. [23] evaluated 17 such patients, with IgA
in eight and IgG in nine. The IgA-LPL group was more likely
to present with B symptoms, a high beta2-microglobulin level
and extramedullary involvement. Compared with patients
with IgM-positive LL, there were similar clinical and
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pathologic features, but a higher mortality within the first year
after diagnosis and worse overall survival.
MYD88 mutation is a hallmark of LL, but is also described
in other lymphomas, including primary testicular DLBCL.
Oishi et al. [24] investigated the mutational status in 23 cases
of testicular DLBCL. There were 17 cases of primary testicular
DLBCL and 6 secondary: 82 % (14/17) and 80 % (4/5) had a
MYD88 mutation. The MYD88 mutational status nor the ex-
pression pattern of the protein affected overall survival, but it
must be stated that only few cases lacked the translocation.
Mantle cell lymphoma (MCL), characterized by the t(11;14)
(q13;q32) and cyclin D1 overexpression, commonly has over-
expression of SOX11. Silencing of SOX11 in MCL cells
promotes the shift into an early plasmacytic differentiation phe-
notype. Ribera-Cortada et al. [25] correlated the terminal B cell
differentiation phenotype in 60 MCL with SOX11-expression:
monotypic plasma cells and lymphoid cells with plasmacytic
differentiation expressing cyclin D1 were observed in 7 (37 %)
SOX11-negative but in none of 41 SOX11-positive MCL.
Furthermore, BLIMP1 and XBP1 expression was also signifi-
cantly more frequent in SOX11-negative than that in -positive
cases (83 vs 34 % and 75 vs 11 %, respectively). However, no
differences in the expression of IRF4/MUM1 were observed.
The authors conclude that their results indicate that SOX11-
negative MCL may be a particular subtype of this tumor char-
ac te r i zed by more f requent morpholog ica l and
immunophenotypic terminal B cell differentiation features that
may be facilitated by the absence of SOX11 transcription factor.
A bit weird conclusion, since basically they merely describe a
feature within a well-defined entity without further arguments
that this feature might indicate a subtype.
A bit better defined variant of MCL is the blastoid subtype,
although there is still substantial interobserver variation in
recognition of the morphological feature. Bhatt et al. [26]
analyzed a series of 169 cases of MCL for the overall survival
of different subtypes. At 5 years, blastoid and diffuse subtypes
had worse survival compared to nodular subtype. However,
the use of stem cell transplantation was associated with lower
risk of death.
Mottok et al. [27] analyzed 45 primary mediastinal B cell
lymphomas (PMBCL) and 3 PMBCL-derived cell lines for
the presence of genetic alterations involving the major histo-
compatibility complex (MHC) class II transactivator CIITA
and found frequent aberrations consisting of structural geno-
mic rearrangements, missense, nonsense, and frame-shift mu-
tations (53 % of primary tumor biopsies and all cell lines).
They also detected intron 1 mutations in 47 % of the cases,
and detailed sequence analysis strongly suggests AID-
mediated aberrant somatic hypermutation as the mutational
mechanism. Furthermore, they demonstrate that genomic
lesions in CIITA result in decreased protein expression and
reduction of MHC class II surface expression, creating an
immune privilege phenotype in PMBCL.
Endemic (e) BL is found in children in equatorial regions
and represents the first historical example of a virus-associated
human malignancy. EBV infection and MYC translocations
are hallmarks of the disease; it is unclear whether other factors
may contribute to its development. Abate et al. [28] analyzed
20 eBL cases from Uganda and showed that the mutational
and viral landscape of eBLwas more complex than previously
reported: other herpesviridae family members were present in
eight cases (40 %), in particular human herpesvirus 5 and
human herpesvirus 8; there was a distinct latency program in
EBV involving lytic genes in association with TCF3 activity;
there were lower frequencies of mutations in MYC, ID3,
TCF3, and TP53, and a higher frequency of mutation in
ARID1A; recurrent mutations in two genes not previously
associated with eBL were identified in 20 % of tumors:
RHOA and cyclin F (CCNF).
Some cases of morphological and phenotypical character-
istic BL lack a MYC translocation. De Falco et al. [29] com-
pared MYC translocation-positive and -negative BL and
found four microRNAs differentially expressed between the
two groups. In MYC translocation-negative cases, they found
overexpression of DNA-methyl transferase family members,
consistent to hypo-expression of the hsa-miR-29 family. This
finding suggests an alternative way for the activation of lym-
phomagenesis in these cases, based on global changes in
methylation landscape, aberrant DNA hypermethylation, lack
of epigenetic control on transcription of targeted genes, and
increase of genomic instability. In addition, they observed an
overexpression of anotherMYC family genemember,MYCN
that may therefore represent a cooperating mechanism of
MYC in driving the malignant transformation in those cases
lacking an identifiable MYC translocation but expressing the
gene at the mRNA and protein levels.
T cell lymphomas
Xue et al. [30] describe their experience with 225 patients with
mature T cell malignancy, including 29 cases of T cell lym-
phoproliferative disorders (T-LPD, all with BM infiltration)
and 196 cases of T-/natural killer-cell lymphoma (T/NKCL,
56 with BM infiltration and 140 without BM infiltration),
figures clearly showing the different epidemiology in
Western countries. The estimated 5-year overall survival rates
of T-LPD and T/NKCL were 97 and 37 %, respectively.
T/NKCL patients with BM infiltration showed significantly
lower response rates and shorter survival than those without
BM infiltration but clinical characteristics were more useful in
effectively stratifying these patients.
Scarfo et al. [31] used advanced bioinformatics on a
gene-expression dataset of 249 cases of T-NHL and normal
T cells. Ectopic coexpression of ERBB4 and COL29A1
genes was detected in 24 % of ALK-negative anaplastic
large cell lymphoma (ALCL) patients. ERBB4 expression
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was confirmed at the protein level by western blot analysis
and immunohistochemistry. They also demonstrated that
ERBB4-truncated forms show oncogenic potentials and
that ERBB4 pharmacologic inhibition partially controls
ALCL cell growth and disease progression in an ERBB4-
positive patient-derived tumorgraft model. This elegant
study identified a new subclass of ALK-negative ALCL
characterized by aberrant expression of ERBB4, which
might potentially be a therapeutic target.
Menon et al. [32] report the clinical, morphologic,
immunophenotypic, and molecular characteristics of 18 cases
of the rare primary central nervous system T-NHL (PCNSTL).
Fifteen cases were classified as peripheral T-NHL, not other-
wise specified, two of which were of γδ T cell derivation and
one was TCR silent; there was one ALCL, ALK-positive and
two ALCL, ALK-negative. The median age of the patients
was 58.5 years (range, 21 to 81 years), with an M:F ratio of
11:7. Regardless of subtype, necrosis and perivascular cuffing
of tumor cells were frequently observed (11/18 cases). CD3
was positive in all cases but one; 10/17 were CD8-positive,
and 5/17 were CD4-positive. Most cases had a cytotoxic phe-
notype with expression of TIA1 (13/15) and granzyme-B
(9/13). Polymerase chain reaction analysis of T cell receptor
γ rearrangement confirmed a T cell clone in all 14 cases with
adequate DNA quality. Next-generation sequencing showed
somatic mutations in 36 % of cases studied; two had >1 mu-
tation, and none showed overlapping mutations. These includ-
ed mutations in DNMT3A, KRAS, JAK3, STAT3, STAT5B,
GNB1, and TET2 genes, genes implicated previously in other
T cell neoplasms. The outcome was heterogenous: two pa-
tients are alive without disease, four are alive with disease,
and six died of disease. In conclusion, PCNSTLs are histolog-
ically and genomically heterogenous with frequent phenotyp-
ic aberrancy and a cytotoxic phenotype in most cases.
Aggerwal et al. [33] encountered a case of S100-positive T-
PLL and decided to study more cases: 19 additional T-PLLs
and 56 other T cell lymphomas that are usually CD4-positive,
including 15 AITL, 24 ALCL, 7 mycosis fungoides/SS, and
10 T-NHL NOS. Thirty percent (6/20) of T-PLLs were S100-
positive, compared with 0/56 other T cell lymphomas. There
were no significant differences between the S100 and S100 T-
PLLs with regard to the male:female ratio (2:1 vs 1:1), age (72
vs 65), peripheral blood lymphocyte count (68 vs 101×10/L),
or median survival (463 vs 578 days, where known). These
results may have some diagnostic implication, but there were
no clinical differences between the S100 and S100 T-PLLs.
New entities/subtypes
Now that more and more knowledge on IgG4-related disease
is accumulating, retrospective studies in different organs re-
veal relevant information. Ferry et al. [34] reviewed 38 cases
presenting with inflammatory lesions in the orbita, previously
diagnosed as orbital inflammatory pseudotumor or chronic
dacryoadenitis. From these, 15 fulfilled the criteria for IgG4-
related disease, nine men and six women, aged 24 to 77 years
(median, 64 years); eight presented in the orbital soft tissue,
six in the lacrimal gland, and one in the canthus; in one case, a
clonal IGH gene rearrangement was detected; four had also
disease in other anatomic sites. There were five patients, one
man and four women, aged 26 to 74 years (median 50 years)
who had orbital lesions (two involving lacrimal gland, three
involving soft tissue) suspicious for, but not diagnostic of,
IgG4-related disease. No patient developed lymphoma, and
no patient died of complications of IgG4-RD. The other 18
patients had a variety of diseases, including granulomatosis
with polyangiitis (3 cases), Rosai-Dorfman disease (1 case),
nonspecific chronic inflammation and fibrosis involving
lacrimal gland or soft tissue (12 cases), and others. Careful
evaluation of histologic and immunophenotypic features and
clinical correlation are required to distinguish orbital IgG4-
RD from other sclerosing inflammatory lesions in the orbit.
Prognostic/predictive factors in lymphoma
Finding predictive markers for expensive drugs is considered
a very important method to reduce health care costs, but is not
easy task. This is examplified by the work of Kenkre et al.
[35]. Based on pre-clinical studies that suggest that single
nucleotide polymorphisms (SNPs) in the Fcγ receptor
(FCGR) genes influence response to rituximab they prospec-
tively obtained specimens of 408 previously untreated, low
tumor burden FL patients treated with single agent rituximab.
The response rate to initial rituximab was 71 % but no FCGR
genotypes or grouping of genotypes were predictive of this
response or response duration. Although this is a disappoint-
ing result, the material and data are unique, and may provide
positive results in the future.
Another potential promising approach was chosen by
Nelson et al. [36] who developed an automated method, the
hypothesized interaction distribution (HID) analysis, to ana-
lyze spatial patterns of multiple biomarkers in tissues and
applied that to tumor-infiltrating lymphocytes in FL. A tissue
microarray of 40 patient samples was used for multispectral
imaging to determine the numbers and locations of CD3(+),
FOXP3/CD3(+), and CD69/CD3(+) T cells. Higher numbers
of all three cell types was related to favorable prognosis. More
importantly, HID analysis of cell pattern identified patient
subgroups with statistically significantly different survival
(36 vs 142 months): a diffuse pattern of FOXP3 and CD69-
positive T cells was related to good prognosis. This approach
indicates hat complex tissue evaluation may result in rele-
vant predictive biomarkers from the tumor microenviron-
ment which may especially be relevant for immunotherapy.
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However, more cases and relation to specific therapies are
needed before such approaches can be introduced in rou-
tine practice.
Chuang et al. [37] took a more traditional approach: they
analyzed known prognostic factors in 174 DLBCL patients
who were older than 60 years. They found that neither
immunoblastic morphology nor GCB/ABC subtype correlated
with survival, but IPI≥3, B symptoms, bone marrow/peripheral
blood involvement, EBER positivity, and CD5 positivity did.
Copie-Bergman et al. [38] analyzed 774 DLBCL cases
characterized for cell of origin by the Hans classifier using
FISH with BCL2, BCL6, MYC, immunoglobulin (IG)K,
and IGL break-apart and IGH/MYC, IGK/MYC, and IGL/
MYC fusion probes. MYC-R was observed in 51/574
(8.9 %) evaluable DLBCL cases. MYC-R cases were pre-
dominantly of the GBC-subtype 37/51 (74 %) with no dis-
tinctive morphologic and phenotypic features. Nineteen
cases were MYC single-hit, and 32 cases were MYC
double-hit (MYC plus BCL2 and/or BCL6) DLBCL.
MYC translocation partner was an IG gene in 24 cases
(MYC-IG) and a non-IG gene (MYC-non-IG) in 26 of 50
evaluable cases. Noteworthy, MYC-IG patients had shorter
overall survival compared with MYC-negative patients,
whereas no survival difference was observed between
MYC-non-IG and MYC-negative patients. These are very
relevant findings indicating that the mere MYC rearrange-
ment is not the optimal biomarker for stratifying patients
for more aggressive therapy.
Miura et al. [39] tried to use a translation of DNA alter-
ations into immunohistochemistry, although it is well known
that there is no good correlation. From their 38 patients treated
with a salvage treatment consisting of rituximab, ifosfamide,
etoposide, cytarabine, and dexamethasone followed by
consolidative high-dose chemotherapies, a total of 17 cases
(45 %) had expression of both MYC and BCL2. This was
associated with a lower overall response rate (35 vs 71 %),
worse 2-year progression-free survival (9 vs 67%) and overall
survival (35 vs 71 %). These are large differences, and the
findings are in line with other studies.
Okina et al. [40] investigated the prognostic relevance of
expression of REV7, a multifunctional protein involved in
DNA damage tolerance, cell-cycle regulation, gene expres-
sion, and carcinogenesis. They give as reason for their study
that its expression is associated with poor prognosis in human
solid tissue cancers, but that the significance of REV7 expres-
sion in hematopoietic malignancies is unclear. They analyzed
83 specimens of de novo DLBCL (38 GCB and 45 ABC)
treated with rituximab, cyclophosphamide, doxorubicin, vin-
cristine, and prednisolone and found aberrant REV7 expres-
sion to be associated with significantly shorter overall surviv-
al, which held up in a multivariate analysis.
These studies reveal once again that we havemany prognostic
factors, but there is still little use of them in clinical trials.
Ancillary techniques
Detection of light chain restriction (LCR) in FFPE-tissue remains
often not successful and is a potential help in some cases. Arora
et al. [41] described a new method, branched-chain RNA
(bRNA) ISH assay for immunoglobulin κ constant (IGKC) and
immunoglobulin λ constant (IGLC). It is a bit irritating that they
use Bclonality^ rather than Blight chain restriction,^ and it should
be well known that these terms cannot be used interchangeably.
They found LCR (light chain ratio>10:1) in 22 of 28 cytology
specimens with a final diagnosis of lymphoma. In two cases, a κ
predominance was present, although the ratio was <10:1. Two B
cell lymphomas lacked IGKC and IGLC, whereas two cases
were negative for the HKG. In 12 of the 20 cases with reactive
lymphoid tissue, bRNA ISH identified a polyclonal lymphoid
population. No light chain messenger RNAwas detected in six
cases (typically those associated with very few B-cells). There
was no comparisonwith the traditional approach, so it is not clear
how much this method will add.
According to Kirsch et al. [42] early diagnosis of cutane-
ous T cell lymphoma (CTCL) is difficult and takes on aver-
age 6 years after presentation, in part because the clinical
appearance and histopathology of CTCL can resemble that
of benign inflammatory skin diseases. This is indeed my
experience as well, but I am not sure whether patients are
helped with an earlier diagnosis. This topic was actually well
reviewed in the previous issue of the Journal of
Hematopathology [43]. According to Kirsch et al. [42], de-
tection of a malignant T cell clone is critical in making the
diagnosis of CTCL, but the T cell receptor γ (TCRγ) poly-
merase chain reaction (PCR) analysis in current clinical use
detects clones in only a subset of patients. This is clearly not
correct; in fact, using the Euroclonality approach, virtually
all lymphomas have a detectable clone [44]. The problem is
actually that clones are present in benign T cell proliferations
of the skin too [45]. Nevertheless, their approach is interest-
ing. High-throughput TCR sequencing (HTS) detected T cell
clones in 46 of 46 CTCL patients, which according to the
authors was more sensitive and specific than TCRγ PCR,
and successfully discriminated CTCL from benign inflam-
matory diseases. The number of patients in the study is
however fair ly low for such strong statements .
Nevertheless, sequence information of antigen receptor
genes in lymphoproliferations is certainly going to change
the way we look into lymphomas as described in my previ-
ous review [46, 47].
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